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Summary
Background Substantial outbreaks of yellow fever in Angola and Brazil in the past 2 years, combined with global 
shortages in vaccine stockpiles, highlight a pressing need to assess present control strategies. The aims of this study 
were to estimate global yellow fever vaccination coverage from 1970 through to 2016 at high spatial resolution and to 
calculate the number of individuals still requiring vaccination to reach population coverage thresholds for outbreak 
prevention.
Methods For this adjusted retrospective analysis, we compiled data from a range of sources (eg, WHO reports and 
health-service-provider registeries) reporting on yellow fever vaccination activities between May 1, 1939, and Oct 29, 
2016. To account for uncertainty in how vaccine campaigns were targeted, we calculated three population coverage 
values to encompass alternative scenarios. We combined these data with demographic information and tracked 
vaccination coverage through time to estimate the proportion of the population who had ever received a yellow fever 
vaccine for each second level administrative division across countries at risk of yellow fever virus transmission 
from 1970 to 2016.
Findings Overall, substantial increases in vaccine coverage have occurred since 1970, but notable gaps still exist in 
contemporary coverage within yellow fever risk zones. We estimate that between 393·7 million and 472·9 million 
people still require vaccination in areas at risk of yellow fever virus transmission to achieve the 80% population 
coverage threshold recommended by WHO; this represents between 43% and 52% of the population within yellow 
fever risk zones, compared with between 66% and 76% of the population who would have required vaccination 
in 1970.
Interpretation Our results highlight important gaps in yellow fever vaccination coverage, can contribute to improved 
quantification of outbreak risk, and help to guide planning of future vaccination efforts and emergency stockpiling.
Funding The Rhodes Trust, Bill & Melinda Gates Foundation, the Wellcome Trust, the National Library of Medicine of 
the National Institutes of Health, the European Union’s Horizon 2020 research and innovation programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Substantial outbreaks of yellow fever in the past 2 years in 
Angola and Brazil, highlight a pressing need to assess 
present control efforts.1 Yellow fever is an acute viral 
haemorrhagic disease that is vaccine preventable, yet it is 
widely distributed in the tropics of Latin America and 
Africa where infections cause an estimated 29 000 to 
60 000 deaths annually.2 Yellow fever virus is transmitted 
to human beings through the bites of infected mosquitoes 
(primarily in the genus Aedes), and is principally 
maintained by a sylvatic (jungle) transmission cycle 
involving non-human primate reservoirs. Urban yellow 
fever outbreaks occur when infected people introduce the 
virus into heavily populated areas with competent vector 
populations and insufficient vaccination coverage. The 
spectrum of human clinical disease caused by the virus is 
broad, ranging from asymptomatic infections and mild 
febrile illness to severe disease and death. A heavy 
emphasis is put on disease control to prevent infections 
because no specific antiviral drug exists for yellow fever.3
If control is insufficient, yellow fever virus can cause 
devastating epidemics, especially in populations where 
vaccine-derived or naturally acquired immunity is low, 
with high case-fatality rates.4 Although elimination of 
yellow fever is not feasible due to its sylvatic reservoir, 
control is achievable due to the availability of a safe, low-
cost, and highly effective vaccine. The yellow fever 
vaccine is a live attenuated vaccine that rapidly 
stimulates immunity (within 30 days for 99% of people 
vaccinated) and can provide lifelong protection.3 
Since the vaccine became available in 1937, multiple 
vaccination strategies have been implemented, 
including the introduction of the vaccine into routine 
childhood schedules, mass preventive and reactive 
campaigns, and the vaccination of travellers to yellow 
fever risk zones. Combined with vector control 
programmes, vaccination has led to a notable reduction 
in disease burden at targeted locations and times.2,4 Yet 
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in many yellow fever risk areas, vaccine coverage 
remains too low to prevent outbreaks. WHO 
recommends population vaccination coverage of 80% or 
more to prevent and control outbreaks.5
The outbreak that started in Angola in December, 2015, 
developed into the largest and most widespread outbreak 
of yellow fever reported in Africa in more than 20 years, 
with 884 confirmed cases in Angola and 78 in neighbouring 
Democratic Republic of the Congo.6,7 Before 2015, yellow 
fever had not troubled Angola since 1988 when a much 
smaller outbreak resulted in 37 cases.8 Angola introduced 
the vaccine into routine infant immunisation programmes 
in 1999,9 but there had been no campaigns to protect adults 
born before 1999 since an outbreak response campaign in 
Luanda in 1988.8
The Angolan outbreak also exposed vulnerabilities in 
the preparedness of local and international agencies to 
respond to such emergencies. Efforts to control the 
outbreak through mass reactive vaccination campaigns 
were hampered by dwindling international vaccine 
supplies and other operational challenges.10 With the 
global yellow fever vaccine emergency stockpile depleted 
by mid-2016, WHO approved the temporary use of 
fractional doses to stretch remaining stocks.11
The course of the Angolan outbreak and international 
response reiterates the need for a sustained policy of 
preventive vaccination of at-risk populations to reduce 
the risk of epidemics. Vaccination campaigns and other 
control strategies require improved understanding of 
present vaccination coverage rates that have resulted 
from cumulative campaigns, within the two risk zones. 
Spatial estimates of vaccination coverage for yellow fever 
have been produced previously2,12 but are often restricted 
to specific age cohorts or countries, with one study2 
estimating population-wide coverage across all at-risk 
countries in Africa, but not for Latin America. The aims 
of this study were to generate yellow fever vaccination 
coverage maps for both Africa and Latin America 
from 1970 to 2016, and to estimate the additional coverage 
needed to prevent further outbreaks.
Methods
Data collation
Yellow fever vaccination is primarily delivered through 
three programme types: routine childhood immunisation 
targeting infants aged around 9 months in at-risk regions; 
periodically conducted mass preventive and outbreak 
response campaigns that target a broader age range; and 
vaccination of people travelling to high-risk areas. To track 
vaccination coverage of the entire population over time for 
this adjusted retrospective analysis, we compiled a dataset 
of the coverage level achieved by each of the first two classes 
of vaccination activity for each age group at specific 
locations and time periods from the earliest use of the 
vaccine in 1939 to 2016. Data on routine infant vaccination 
coverage were obtained from annual national estimates, 
based on health-service-provider registries of yellow fever 
vaccination coverage reported yearly by each at-risk country 
Research in context
Evidence before this study
We searched PubMed on May 24, 2017, using the search terms 
“yellow fever”[All Fields] AND (“vaccine coverage”[All Fields] 
OR “vaccination coverage”[All Fields] OR “immunization 
coverage”[All Fields] OR “immunisation coverage”[All Fields]), 
without any date or language restrictions. This search returned 
65 articles, of which 12 contained spatial information on yellow 
fever vaccination coverage. Eight of these articles reported 
coverage estimates derived from single surveys done for 
individual nations at a particular timepoint. Two articles 
presented descriptive spatial analyses of vaccination coverage 
data and another analysed the cost-effectiveness of introducing 
routine yellow fever vaccination, which included simulated 
estimates of future coverage. Garske and colleagues estimated 
population-wide coverage across all at-risk countries on the 
African continent through the decades from 1960 to 2010, but 
not, however, for Latin America. In 2017, WHO published 
estimates of the number of vaccine doses required for each 
region to support the Global Strategy to Eliminate Yellow Fever 
Epidemics, 2017–2026.
Added value of this study
The aims of this study were to generate yellow fever 
vaccination coverage maps for both Africa and Latin America 
from 1970 to 2016, and to estimate the additional coverage 
needed to prevent further outbreaks. We used a similar 
approach to the previously published map for Africa, but 
importantly for this study, we assessed the range of estimates 
produced when alternative vaccination-targeting scenarios are 
considered. We also included more recent vaccination coverage 
data and extended the map to Latin America. Overall our study 
highlights the stark differences in vaccination coverage 
between Latin America and Africa. Our estimates of the number 
of individuals who still require vaccination to achieve target 
thresholds for the prevention of outbreaks are provided at 
district level, and these numbers can be recalculated with our 
coverage estimates and any new threshold.
Implications of all the available evidence
Our coverage map for 2016 highlights key gaps in present 
levels of vaccination coverage within yellow fever risk zones and 
enables the identification of areas that currently do not meet 
the WHO recommendation of 80% population coverage, and 
are therefore at risk of an outbreak. Our regional and global 
estimates of the number of individuals requiring vaccination to 
prevent future outbreaks corroborate WHO estimates, and our 
district estimates can assist in the planning of vaccine delivery, 
emergency stockpiling, and manufacturing surge capacity.
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to WHO and UNICEF.13,14 Data on mass preventive and 
outbreak response campaigns were primarily extracted 
from online sources, including the Weekly Epidemiological 
Records,15 Disease Outbreak News,16 Morbidity and 
Mortality Weekly Reports,17 and two WHO reports: one on 
mass vaccination in west and central Africa through 
the 1940s to 1960s,18 and another on the 2016 epidemic in 
the Democratic Republic of the Congo.19 The Brazilian 
national immunisation programme information system 
also provided more detailed data for Brazil from 2006 to 2015. 
Descriptions of each vaccination and demographic data 
type, along with details on data processing and collation, 
are provided in the appendix (pp 1–9). Table 1 shows a 
summary of datasets obtained via the websites of WHO,13–16 
United Nations World Population Prospects,20,21 and the US 
Centers for Disease Control and Prevention.17
Application of correction terms to non-survey 
vaccination data
Where available, vaccination data from post-campaign 
coverage surveys were used in preference to 
administratively reported coverage data (ie, health service 
provider reported estimates) because these generally 
provide more reliable coverage estimates. Additionally, 
all administratively reported coverage data were 
multiplied by bias correction terms to adjust for 
variability in health system reporting reliability. These 
data included all routine vaccination data and any 
preventive or outbreak response data for which the 
percentage of the target population vaccinated was not 
estimated from a post-campaign coverage survey (only 
six campaigns reported results of a post-campaign 
survey). We calculated bias correction terms for each 
country and year as ratios of survey-derived Global 
Burden of Disease Study22 estimates of mean coverage 
for third dose of diphtheria-tetanus-pertussis-containing 
vaccine (DTP3) and WHO/UNICEF Joint Reporting 
Process administratively reported estimates.13,23 Coverage 
for DTP is often used as the main indicator for 
performance of routine vaccination services.24 Data were 
available to calculate bias correction terms for each 
country from 1980 to 2015. For outbreak response 
campaigns done before 1980, bias corrections terms 
for 1980 were applied, and for 2016, correction terms 
for 2015 were used. WHO also corrects reported 
administrative data,25 but the DTP terms were more 
comprehensive in time and space. The bias correction 
terms for each country and year are available in Dryad.
Estimation of vaccination coverage
Using the age, time, and location specific vaccination 
coverage and population datasets, we tracked each age 
cohort (from ages 0 to 99 years) in every district through 
time—from their birth year through to 2016 (ie, the 
earliest cohort was born in 1871 to track coverage of 
individuals aged 99 years in 1970)—updating the 
coverage level whenever a routine, preventive, or 
outbreak response campaign was conducted. We 
assumed that the mortality rate for vaccinated and 
unvaccinated individuals was the same and that no 
mixing of populations between districts occurred.
Because the strategies for within-population targeting of 
vaccinations were unknown, we generated three alternative 
vaccination coverage estimates, each corresponding to one 
of three targeting scenarios. (1) Untargeted, unbiased: 
assuming vaccination history was not taken into account 
and all individuals had an equal chance of receiving a 
vaccine irrespective of their previous vaccination status. 
(2) Targeted: assuming that vaccination history was taken 
into account and only non-vaccinated individuals were 
targeted by immunisation campaigns. (3) Untargeted, 
biased: assuming that vaccination history was not taken 
into account and that previously vaccinated individuals 
were more likely to be targeted inadvertently (ie, because of 
demographic biases in vaccination uptake). In the 
untargeted, biased scenario, for each vaccination 
campaign, we assumed that all previously vaccinated 
individuals received vaccines before any unvaccinated 
individuals. This scenario produces maximally conservative 
estimates of vaccination coverage, whereas estimates from 
the targeted scenario are maximally optimistic. Further 
detail on vaccination coverage calculations is provided in 
the appendix (p 9).
Estimation of the number of people requiring 
vaccination in 2016 to meet targets
Using each of the three sets of values of vaccination 
coverage for 2016 based on optimistic through to 
conservative scenarios of historical targeting, we 
calculated three sets of estimates for the number of 
individuals across all ages who still require vaccination to 
reach the 80% population coverage threshold 
recommended by WHO to prevent outbreaks5 for each at-
risk district (districts classified by the WHO range maps 
See Online for appendix
Years searched/ 
available
Date accessed Data extracted
WHO Weekly Epidemiological Records15 1970–2016 Aug 26, 2016 Mass vaccination
WHO Disease Outbreak News16 1996–2016 Aug 26, 2016 Mass vaccination
CDC Morbidity and Mortality Weekly Reports17 1982–2016 Oct 3, 3016 Mass vaccination
WHO-UNICEF reviews of national immunisation 
coverage14
1980–2014 Aug 26, 2016 Routine 
vaccination
Country-level estimates of routine infant 
immunisation coverage from WHO-UNICEF Joint 
Reporting Form for yellow fever virus and DTP313
1980–2015 Oct 3, 2016 Routine 
vaccination
UNWPP annual population by 5-year age groups20 1950–2015 Oct 13, 2016 Demographic
UNWPP infant mortality rate21 1950–2015 Oct 10, 2016 Demographic
UNWPP under-5 mortality21 1950–2015 Oct 10, 2016 Demographic
Vaccination activity and demographic data accessed via WHO, UNWPP, and CDC websites. Mass vaccination was 
regarded as preventive and outbreak response vaccination activities. CDC=Centers for Disease Control and Prevention. 
DTP3=third dose of diphtheria-tetanus-pertussis-containing vaccine. UNWPP=United Nations World Population 
Prospects.
Table 1: Summary of online data sources
For Dryad please see http://dx.
doi.org/10.5061/dryad.5ps8j
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for yellow fever as either completely or partially endemic 
or as having low potential for exposure26). That is, the 
number of people who would require supplementary 
vaccination under the assumption that, in the future, 
unvaccinated individuals will be targeted (ie, the most 
optimistic scenario) and that the 80% coverage threshold 
applies across all populations. The resulting figures were 
then summed to obtain national, regional, and global 
estimates. The number of individuals still requiring 
vaccination for each at-risk district is provided in Dryad. 
We also calculated a global estimate of the number of 
people who would have required vaccination in 1970 for 
comparison.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Figure 1: Yellow fever vaccination coverage from 1970 to 2016
Estimated proportion of the population across all age cohorts who have ever received a yellow fever vaccine at the beginning of each decade (and in 2016) at the 
second administrative level for countries at risk of yellow fever virus transmission, based on the untargeted, unbiased vaccination-targeting scenario.
C
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100%
80%
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Results
Our estimates of yellow fever vaccination coverage, based 
on the untargeted, unbiased campaigns scenario, 
highlight substantial international and subnational 
variation, both spatially and temporally (figure 1). 
Population vaccination coverage rates in countries within 
risk zones ranged from a maximum of 100% in parts of 
Amazonas State, Brazil, to zero coverage in parts of 
central and east Africa (routine infant immunisation 
programmes have not yet been introduced in these areas). 
Throughout the decades, vaccination coverage rates were 
higher overall in Latin America compared with Africa. 
Coverage rates were particularly high in Brazil during 
the 1970s and 1980s, declined slightly in the 1990s, and 
were again very high in most parts of the country by 2016. 
A similar pattern of waxing and waning was seen for 
many countries in west and central Africa. Vaccination 
coverage rates were moderately high throughout these 
two regions in the 1970s, but coverage declined 
between 1970 and 2000, before reaching high rates again 
by 2016. However, several localised areas did achieve high 
coverage rates at various timepoints, including parts of 
Senegal, The Gambia, Ghana, and Mali.
When we considered contemporary coverage (ie, the 
2016 coverage map; figure 1), important gaps were 
apparent within the risk zones of Africa, including large 
areas of central and east Africa and parts of Nigeria, 
Niger, Sierra Leone, Liberia, and Guinea-Bissau. In 
Latin America, low coverage was estimated for Guyana, 
Suriname, French Guiana, and Colombia. Vaccination 
coverage estimates for all at-risk districts for each year 
presented in figure 1 are provided in Dryad.
We found substantial geographical variation in the 
sensitivity of estimated vaccination coverage rates to 
alternative assumptions for vaccination-targeting, which 
shows the potential effect of an important area of 
uncertainty in vaccination data. The percentage 
differences (figure 2) in coverage between the targeted 
versus the untargeted, biased alternative vaccination-
targeting scenarios range from 0% difference in most of 
central and east Africa and most countries in Latin 
America, to up to 73% in a small number of municipalities 
within Brazil.
Country-level estimates of yellow fever vaccination 
coverage by age group in 2016 highlight the progress of 
routine infant immunisation programmes in protecting 
Figure 2: Contemporary yellow fever vaccination coverage scenarios
Estimated proportion of the population in 2016 across all age cohorts who have ever received a yellow fever vaccine at the second administrative level in 
countries at risk of yellow fever virus transmission. Vaccination coverage was calculated using three alternative vaccination-targeting scenarios: 
(A) targeted; (B) untargeted, unbiased; and (C) untargeted, biased. (D) Percentage difference in coverage between targeting scenarios A and C.
100%
80%
0%
100%
0%
A Targeted B Untargeted, unbiased
C Untargeted, biased D A versus C 
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children and young adults on both continents (figure 3), 
but they also revealed coverage gaps in adult populations 
for most countries. Angola, Cameroon, Guinea, Senegal, 
Togo, Paraguay, Bolivia, and Brazil were exceptions to 
this, with moderate to high coverage estimated across all 
age groups. Estimates by age group from 1970 to 2010 are 
provided in the appendix (pp 10–11).
From the 2016 outputs, we estimated that between 
393·7 million and 472·9 million individuals still require 
vaccination within at-risk districts globally, to achieve 
the 80% population coverage threshold recommended 
by WHO to prevent outbreaks (table 2). Between 361·4 
and 396·0 million of these people live in Africa and 
between 32·2 and 76·9 million live in Latin America. 
The national estimates of the total number of individuals 
requiring vaccination within each country are provided 
in table 2 and disaggregated values for each district are 
available in Dryad. All countries except Bolivia, Peru, 
and Senegal contained at-risk districts with less than 
80% population coverage under all three historical 
vaccination-targeting scenarios.
Discussion
We mapped population-wide vaccination coverage for 
yellow fever across all countries within risk zones 
from 1970 to 2016. Present vaccination coverage is the 
result of cumulative campaigns, therefore it is important 
to incorporate information on past vaccination strategies 
to understand the present position. Our coverage map 
for 2016 highlights key gaps in present levels of 
vaccination coverage within yellow fever risk zones and 
enables the identification of areas that currently do not 
meet the WHO recommendation of 80% population 
coverage, and are therefore at risk of an uncontrolled 
outbreak.
Our conservative estimates of the number of people 
requiring vaccination in 2016 to meet the 80% threshold 
are approximately 10% smaller for Africa and 3% greater 
for Latin America (table 2) than the WHO’s estimates of 
doses required for mass campaigns as part of the Global 
Strategy to Eliminate Yellow Fever Epidemics, 2017–2026.5 
Our district estimates can assist in the planning of 
vaccine delivery, and if combined with estimates of the 
number of doses required for future routine infant 
immunisation programmes, they can be used in the 
planning of emergency stockpiling and manufacturing 
surge capacity. Notably, the 80% threshold is an average; 
in reality, the critical vaccination coverage needed to 
prevent outbreaks is expected to vary substantially 
across different settings depending tightly on the basic 
reproduction number, R0.27 Using our estimates of the 
proportion vaccinated for each district, others can 
recalculate the number of individuals requiring 
vaccination to reach any new threshold.
The estimates of vaccination coverage over time show 
the cumulative effect of multiple different vaccination 
Figure 3: National yellow fever vaccination coverage by age group
Estimated proportion of individuals within each age group in 2016 who have ever received a yellow fever vaccine for each country at risk of yellow fever virus 
transmission, based on the untargeted, unbiased vaccination-targeting scenario. Plots for the beginning of each decade from 1970 to 2010 are provided in the 
appendix (pp 10–11).
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strategies combined with the different demographic 
profiles of the two at-risk regions. Our results for Africa 
from 1970 to 2010 corroborate the analysis by Garske 
and colleagues.2 We used a similar approach but, 
importantly for this study, we assessed the range of 
estimates produced when alternative vaccination-
targeting scenarios are considered. We also included 
more recent vaccination coverage data and extended the 
map to Latin America. Overall our study highlights the 
stark differences between Latin America and Africa, 
which might, in part, account for the difference in the 
observed number of outbreaks between these two 
regions.4
Combined with vector control efforts, high levels of 
vaccination coverage in Brazil have led to a substantial 
reduction in the number of yellow fever cases since 
the 1930s, especially cases arising from urban 
transmission cycles. Coverage rates were particularly 
high in Brazil during the 1970s and 1980s, but then 
declined slightly, resulting in a resurgence of sylvatic 
transmission in the 1990s and early 2000s.4 This 
resurgence prompted further mass vaccination 
campaigns and the resulting 2016 vaccination coverage 
rates were estimated to be very high for most parts of the 
country. We estimated lower levels of vaccination 
coverage at the eastern edge of the risk zone in Brazil 
for 2016, including within the state of Minas Gerais, 
where a yellow fever outbreak arose in December, 2016.1
The moderately high vaccination coverage rates 
throughout much of west and central Africa in the 1970s 
(figure 1) were the result of mass preventive campaigns 
through the 1940s to 1960s,18 which reduced the number 
of outbreaks. Coverage waned between 1960 and 2000 in 
most areas due to limited vaccination activity, the birth of 
new unvaccinated cohorts, and the gradual reduction in 
the proportion of older protected cohorts through 
mortality. Vaccine stock shortages, which have been 
frequently reported in the African region,5 would have 
also contributed to lower than recommended coverage 
levels. Several localised areas, including parts of Senegal, 
The Gambia, Ghana, and Mali, were exceptions to this 
pattern because they conducted outbreak response 
campaigns that reached high levels of coverage. In 2010, 
vaccination coverage in Angola was estimated to be low 
across all districts, except Luanda with 64% coverage. 
Following outbreak response campaigns in 2016, 
coverage had reached nearly 90% for Luanda, and just 
under the 80% threshold across a number of other 
districts in the north and west of the country. Additionally, 
the most recent Disease Outbreak News report28 included 
in this study indicated that vaccination campaigns were 
ongoing in several of these districts.
Many countries in west and central Africa introduced 
the yellow fever vaccine into their routine infant 
immunisation schedules between the late 1980s and 
early 2000s,9 but the effect of these efforts will take time 
to affect population level coverage in the absence of 
Only at-risk districts* All districts†
Conservative Untargeted Optimistic Conservative Untargeted Optimistic
Nigeria 112·0 101·2 95·9 112·0 101·2 95·9
Ethiopia 74·4 74·3 74·2 80·9 80·8 80·8
Kenya 32·4 32·4 32·4 37·6 37·6 37·6
Uganda 32·2 32·2 32·2 32·4 32·4 32·4
Democratic Republic 
of the Congo
30·4 28·6 26·9 34·9 32·5 30·3
Sudan 12·9 12·5 12·1 19·5 19·0 18·7
Rwanda 10·2 10·2 10·2 10·2 10·2 10·2
South Sudan 9·8 9·8 9·8 9·8 9·8 9·8
Niger 9·8 9·6 9·5 9·8 9·6 9·5
Burundi 8·9 8·9 8·9 8·9 8·9 8·9
Chad 8·4 8·2 8·0 8·5 8·3 8·1
Ghana 6·7 5·9 5·4 6·7 5·9 5·4
Côte d’Ivoire 6.4 5.9 5.5 6.4 5.9 5.5
Benin 4·8 4·6 4·4 4·8 4·6 4·4
Burkina Faso 4·3 3·9 3·6 4·3 3·9 3·6
Mali 4·7 3·7 3·2 4·7 3·7 3·2
Angola 4·6 3·5 3·3 4·6 3·5 3·3
Cameroon 3.3 3.0 2.8 3.3 3.0 2.8
Sierra Leone 2·5 2·5 2·5 2·5 2·5 2·5
Congo (Brazzaville) 3·0 2·2 1·7 3·0 2·2 1·7
Central African 
Republic
2·3 2·2 2·1 2·3 2·2 2·1
Mauritania 2·1 2·0 2·0 3·3 3·2 3·2
Guinea 2·9 1·6 0·2 2·9 1·6 0·2
Liberia 1·6 1·6 1·6 1·6 1·6 1·6
Guinea-Bissau 1·1 1·1 1·1 1·1 1·1 1·1
Gabon 1·0 1·0 1·0 1·0 1·0 1·0
Senegal 2·2 0·7 0·0 2·2 0·7 0·0
Equatorial Guinea 0·7 0·7 0·7 0·7 0·7 0·7
Togo 0·4 0·3 0·2 0·4 0·3 0·2
The Gambia 0·1 0·1 0·1 0·1 0·1 0·1
Tanzania ·· ·· ·· 41.7 41·7 41·7
Eritrea ·· ·· ·· 5·3 5·3 5·3
Somalia ·· ·· ·· 4·7 4·7 4·7
Zambia ·· ·· ·· 1·5 1·5 1·5
São Tomé 
and Príncipe
·· ·· ·· 0·1 0·1 0·1
Totals for Africa 396·0 373·9 361·4 473·4 450·8 437·8
Colombia 23·5 23·0 22·7 29·9 29·3 29·0
Brazil 40.3 6.8 2.1 121.8 49.7 27.1
Venezuela 6·2 4·7 3·9 12·6 10·3 9·1
Panama 1·0 1·0 1·0 1·0 1·0 1·0
Peru 3·1 0·8 0·0 18·7 15·3 14·1
Ecuador 0·6 0·6 0·6 8·7 8·7 8·7
Paraguay 0·5 0·5 0·4 0·5 0·5 0·4
Guyana 0·4 0·4 0·4 0·4 0·4 0·4
Suriname 0·4 0·4 0·4 0·4 0·4 0·4
Argentina 0·2 0·2 0·2 1·3 1·3 1·3
Trinidad and Tobago 0·2 0·2 0·2 0·2 0·2 0·2
French Guiana 0·2 0·2 0·2 0·2 0·2 0·2
(Table 2 continues on next page)
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campaigns targeting adults born before the late 1980s 
(figure 3). For adequate protection against outbreaks, the 
vaccine should be introduced into routine infant 
immunisation schedules, followed by catch-up 
campaigns for adult populations. The success of this 
approach is exemplified by The Gambia, which reported 
no locally acquired cases for more than two decades 
when in 1979 they conducted a post-outbreak mass 
vaccination campaign targeting all ages and in tandem 
introduced the vaccine into their routine infant 
immunisation schedule.9 Increased coverage rates were 
achieved overall in west and central Africa in 2010 and 
2016 after large-scale preventive campaigns supported by 
the Yellow Fever Initiative and Gavi, the Vaccine Alliance, 
were implemented in 2006.29
Our dataset of vaccination coverage, compiled from a 
range of sources, highlights concerns about the 
completeness and accuracy of the reports on vaccination 
activity. To assess the effect of uncertainty regarding 
whether vaccination history was taken into account when 
targeting individuals in mass campaigns, we calculated 
vaccination coverage using three different vaccination 
coverage scenarios ranging from conservative to 
optimistic. Brazil was most sensitive to different 
assumptions about the vaccination-targeting scenarios 
(figure 2) because they have conducted sustained 
vaccination activities since the 1940s; when vaccination 
coverage in each age cohort was tracked through time, 
there was ample opportunity for alternative estimates to 
diverge from one another. Additionally, the vaccination 
activity data for Brazil used in our analysis were more 
complete, and spatially and temporally disaggregated, 
than they were for other countries. Lessler and 
colleagues30 describe an approach for estimating 
uncertainties associated with vaccination targeting by 
using administrative data and cross-sectional survey 
data, across a range of ages, on measles vaccination to 
calculate the size of the population systematically missed 
by vaccination activities in a particular country. However, 
insufficient cross-sectional survey data on yellow fever, 
needed for this method, are available, especially for adult 
populations.
Estimates of vaccination coverage at the country or 
province level, including most of the routine infant 
vaccination data and much of the preventive and reactive 
mass vaccination campaigns used in this study, often 
smooth out important sources of spatial heterogeneity. 
Characterisation of such heterogeneities is important for 
planning spatially targeted interventions. High-
resolution vaccination coverage data, such as that used in 
this Article for Brazil, would improve certainty of 
coverage estimates for other countries. Data from 
household surveys would afford increased certainty and 
resolution of vaccination coverage estimates, but are only 
available for limited times, locations, and age cohorts, 
and as such require geospatial modelling to interpolate 
across time and space.
Our maps of vaccination coverage do not necessarily 
translate into an absolute measure of vaccine-derived 
immunity because vaccine efficacy is not 100% (although 
evidence suggests that yellow fever vaccine efficacy is 
close to 100% and WHO concluded that a single dose 
gives lifelong protection).3 Likewise, the proportion of 
individuals with immunity to yellow fever virus is not 
necessarily equivalent to the proportion of individuals 
with vaccine-derived immunity; this is due to the possible 
acquisition of immunity via natural infection, especially 
where outbreaks have occurred. Our coverage estimates 
could be combined with estimates of vaccine efficacy, 
and of natural infection rates to estimate the number of 
individuals susceptible to symptomatic yellow fever 
infection and to quantify the effect of vaccination on 
yellow fever incidence and outbreak potential.
Yellow fever cannot be eliminated due to the presence 
of non-human wildlife reservoirs, which maintain the 
sylvatic transmission cycle of the virus in non-urban 
settings, but the risk of a yellow fever epidemic can be 
eliminated if effective vector control, vaccination, and 
disease surveillance are enforced and maintained. The 
results of this study highlight both important progress 
and gaps in yellow fever vaccination coverage within risk 
zones and provide credible estimates of the doses 
required for supplementary campaigns. This information 
should be coupled with fine-scale estimates of 
geographical disease risk to identify populations most 
susceptible to yellow fever infection. Only then can policy 
makers begin to develop the most effective vaccination 
strategies to prevent outbreaks.
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Table 2: Number of individuals in millions still requiring vaccination in 2016
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